Membres du laboratoire

• Alain Zgheib, Assistant de recherche
• Abdallah Fallah, étudiant Ph.D.
• Rosalie Zilinski, étudiante M.Sc.
• Anes Boudah, étudiant M.Sc.
• Marieme Thioro Faye, étudiante M.Sc.
• Maellis Payet-Desruisseaux, étudiante M.Sc.

Alumni

• Dr Mayya Meriane
• Dr Amel Guezguez
• Dr Reshu Gupta
• Dr Chirine Toufaily
• Dr David Beauchemin
• Dr Ana Carolina B. M. Martin
• Dr Khadidja Haidara
• Dr Sylvie Lamy
• Dr Michel Demeule
• Dr Cyndia Charfi
• Dr Amira Ouanouki
• Dr Khalil Abdelbaqi
• Dre Isabelle Cousineau
• Dre Maria de la Cruz Dominguez Punaro
• Dr Bogdan Alexandru Danalache
• Dr Naoufal Akla
• Dr Emmanuelle Boscher
• Jean-Christophe Currie
• Anissa Belkaid
• Simon Fortier
• Simon Lord-Dufour
• Martha Maria Cajina Herrera
• Carl Laflamme
• Asmaa Sina
• Elizabeth Tahanian
• Sébastien Proulx-Bonneau
• Éric Vaillancourt-Jean
• Naoufal Akla
• Rima Chokor
• Alain Zgheib
• Paula Liana Moldovan
• Michel Desjarlais
• Aroua Ben Saad
• Hana Benenemissi
• Pascale Gagné
• Samuel Burke-Nanni
• Samuel Sheehy
• Bayader Annabi
• Amélie Vézina
• Jonathan Pratt
• Laurence Lejeune
• Evelyne Muhire
• Clémence Bensiali-Haddaud
• Djahida Djerir
• Amira Ouanouki
• Wendenmi Tiziana Manuella Dao
• Marbelis Francisco Fernandez
• Audrey-Ann Sicard
• Samaneh Kamyabiazar
• Souad Djediai
• Véronique Lullier
• Virginie Desse
• Valérie Cabana
• Layal El Cheikh-Hussein
• Celia Kassouri
• Loraine Gresseau
• Sahily Rodriguez Torres
• Narjara Gonzalez Suarez
• Sima Torabidastgerdooei
• Meriem Benhamida
• Carolane Veilleux
• Sarah Kym Pepin
• Kaenon Prisca-Désiré Gnao
• Marie-Eve Roy
• Angélique Sabaoth Konan

Chaire de Recherche en Prévention et Traitement du Cancer, Directeur

Réseau de recherche sur le cancer, (FRSQ), Membre

Réseau de Thérapie Cellulaire et Tissulaire ThéCELL, Membre

Réseau pour Avancer la REcherche sur les maladies rares au Québec (FRSQ), Membre

Centre d’Excellence en Recherche sur les Maladies Orphelines, Membre

Coalition Priorité Cancer au Québec, Membre

Réseau CommunAutés Rurales et Éloignées en Santé | CARES (FRSQ), Membre

Regroupement intersectoriel de recherche en santé de l’Université du Québec (RISUQ), Membre

Canadian Glycomics Network, Membre

• Danalache BA, Faye MT, ANNABI B (2026) Advancing precision chemotherapy and overcoming resistance mechanisms through Sortilin-directed peptide-drug conjugates.  Critical Reviews in Oncology / Hematology  225(2026):105479
• Danalache BA, Fallah A, Mercier F, ANNABI B (2026) The glucose-6-phosphatase system in cancer: From endoplasmic reticulum glucose-6-phosphate flux to stemness, immune escape, and therapeutic vulnerability.  Frontiers in Oncology  16:1912198
• Payet-Desruisseaux M, Zgheib A, Danalache BA, Desjarlais M, ANNABI B (2026) Disrupting the TGF-β-regulated epithelial-mesenchymal transition, apoptotic and autophagic phenotypes of 3D glioblastoma spheroids via glycolytic inhibition.  Exploration of Targeted Anti-tumor Therapy  2026;7:1002364
• Akla N, Boudah A, Bertomeu T, Chatr-Aryamontri A, Desjarlais M, ANNABI B (2026) CRISPR-based chemogenomic profiling reveals redox vulnerabilities to epigallocatechin-3-gallate and green tea polyphenol extract.  Redox Biology  90:104047
• Touaibia M, Boudah A, Zgheib A, Danalache BA, ANNABI B (2026) Targeting of vasculogenic mimicry and of stemness transcriptional signature in human ovarian cancers: New emerging roles of caffeic acid phenethyl ester analogs.  Frontiers in Pharmacology  17:1787101
• Fallah A, Zgheib A, Danalache BA, Eliopoulos N, ANNABI B (2026) HIF-1α-Driven SLC37A2/SLC37A3/G6PC3 Transcriptional reprogramming shapes glioblastoma stemness in 3D neurospheres.  Biochemical and Biophysical Research Communications  794:153050
• Konan AS, Zilinski R, Tadrous M, Zgheib A, Gaudreault R, ANNABI B (2025) Synthetic 1,3,6-tri-O-galloyl-α-D-glucose mimics the Hippo pathway inhibitor VT107 in suppressing concanavalin A-induced inflammation in human glioblastoma cells  Journal of Inflammation Research  18:17523-17535
• Fallah A, Payet-Desruisseaux M, Zgheib A, Danalache BA, Eliopoulos N, ANNABI B (2025) Chemopreventive targeting of oncogenic stemness: EGCG-mediated suppression of the HIF-1α-PPARg-cancer stem cells transcriptional signature in 3D glioblastoma spheroids.  Journal of Cancer  16(15):4302-4315
• Zilinski R, Konan AS, Zgheib A, Eliopoulos N, Boudreau LH, ANNABI B (2025) Hippo pathway suppression reprograms TNFα-primed glioblastoma extracellular vesicles cargo to drive mesenchymal stem/stromal cells vasculogenic mimicry  Cell Communication and Signaling  23(1):434
• Roy ME, Zgheib A, Eliopoulos N, ANNABI B (2025) A SORT1/EGFR molecular interplay as a prognostic biomarker in glioblastoma vasculogenic mimicry: Implications in cancer stemness and drug resistance.  BMC Cancer  25(1):1348
• Pepin SK, Zgheib A, Roy ME, ANNABI B (2025) Quercetin targeting of TGFb-primed human MDA-MB-231 triple-negative breast cancer cells : Linking epithelial-to-mesenchymal transition to cell senescence and fibrosis.  Molecular Biology Reports  52(1):725
• Gnao KPD, Roy ME, Zgheib A, Desjarlais M, ANNABI B (2025) Evidence of a functional Smad2/3 signaling axis and TGFβ-mediated autocrine transcriptional regulation of in vitro vasculogenic mimicry in mesenchymal stem/stromal cells.  Oncology Letters  30:405
• Veilleux C, Roy ME, Zgheib A, Desjarlais M, ANNABI B (2025) Evidence for a JAK2/STAT3 proinflammatory and vasculogenic mimicry interrelated molecular signature in adipocyte-derived mesenchymal stromal/stem cells.  Cell Signaling and Communication  23(1):291
• Berenguer A, Zgheib A, Salomón SI, Manso AP, Osoria LAF, Piloto-Ferrer J, ANNABI B (2025) Xanthatin nanocrystals exert anti-inflammatory properties against TNF-primed 2D monolayers and in 3D spheroids of human HT29 colorectal cancer cells.  Discover Nano  20(1):83
• Veilleux C, Khalifa J, Zgheib A, Gaudreault R, ANNABI B (2025) Probing into the anti-inflammatory and anti-invasive properties of 1,3,6-tri-O-galloyl-α-D-glucose (α-TGG) against glioblastoma and triple-negative breast cancer-derived cell models.  Current Research in Pharmacology and Drug Discovery  8:100219
• Akla N, Veilleux C, ANNABI B. (2025) The chemopreventive impact of diet-derived phytochemicals on the adipose tissue and breast tumor microenvironment secretome.  Nutrition and Cancer  77(1):9-25
• Veilleux C, Roy ME, ANNABI B (2025) Assessing MMP-2/9 proteolytic activity and activation status by zymography in preclinical and clinical tissue samples.  Methods in Molecular Biology.  2918:165-176.
• Roy ME, Elimam R, Zgheib A, ANNABI B (2024) Pharmacological probing of clinically relevant Hippo pathway inhibitors reveals a role for transcription factor YAP1 in glioblastoma in vitro vasculogenic mimicry regulation.  Journal of Cellular and Molecular Medicine  28(24):e70304
• Roy ME, Veilleux C, ANNABI B. (2024) In vitro biomaterial priming of human mesenchymal stromal/stem cells into 3D capillary-like structures : Implication of the Src/JAK/STAT3 signaling pathway in vasculogenic mimicry  Scientific Reports  14(1):21444
• Roy ME, Veilleux C, Paquin A, Gagnon A, ANNABI B (2024) Transcriptional regulation of CYR61 and CTGF by LM98, a synthetic YAP/TEAD inhibitor that targets in vitro vasculogenic mimicry in glioblastoma cells.  Anti-Cancer Drugs  35(8):709-719
• Demeule M, Currie JC, Charfi C, Zgheib A, Cousineau I, Lullier V, Béliveau R, Marsolais C, ANNABI B (2024) Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing.  Frontiers in Immunology  15:1355945
• Torabidastgerdooei S, Roy ME, and ANNABI B (2023) A molecular signature for the G6PC3 / SLC37A2 / SLC37A4 interactors in glioblastoma disease progression and in the acquisition of a brain cancer stem cell phenotype.  Frontiers in Endocrinology  14:1265698
• Gonzalez Suarez N, Fernandez-Marrero Y, Hébert MPA, Roy ME, Boudreau LH, ANNABI B (2023) EGCG inhibits the inflammation and senescence inducing properties of MDA-MB-231 TNBC cells-derived extracellular vesicles in human adipose-derived mesenchymal stem cells.  Cancer Cell International  23(1):240
• Rodriguez Torres S, Gresseau L, Benhamida M, Fernandez-Marrero Y, ANNABI B (2023) Epigallocatechin-3-gallate prevents the acquisition of a cancer stem cell phenotype in ovarian cancer tumorspheres through the inhibition of Src/JAK/STAT3 signaling.  Biomedicines  11(4):1000
• Gresseau L, Roy ME, Duhamel S, ANNABI B (2022) A signaling crosstalk links Snail to the 37/67 kDa laminin-1 receptor ribosomal protein SA and regulates the acquisition of a cancer stem cell molecular signature in U87 glioblastoma neurospheres.  Cancers  14(23):5944
• Kassouri C, Rodriguez Torres S, Gonzalez Suarez N, Duhamel S, ANNABI B (2022) EGCG prevents the transcriptional reprogramming of an inflammatory and immune-suppressive molecular signature in macrophage-like differentiated human HL60 promyelocytic leukemia cells.  Cancers  14(20):5065
• Gonzalez Suarez N, Fernandez-Marrero Y, Torabidastgerdooei S, ANNABI B (2022) EGCG prevents the onset of an inflammatory and cancer-associated adipocyte-like phenotype in adipose-derived mesenchymal stem/stromal cells in response to the triple-negative breast cancer secretome.  Nutrients  14(5):1099
• Demeule M, Charfi C, Currie JC, Zgheib A, Danalache BA, Béliveau R, Marsolais C, ANNABI B (2022) The TH1902 docetaxel peptide-drug conjugate inhibits xenografts growth of cancer stem-like cells derived from human SORT1-positive ovarian and triple-negative breast cancers.  Pharmaceutics  14(9):1910
• Pratt J, Haidara K, ANNABI B (2022) MT1-MMP expression levels and catalytic functions dictate LDL receptor-related protein-1 ligand internalization capacity in U87 glioblastoma cells.  International Journal of Molecular Sciences  23(22):14214
• Currie JC, Demeule M, Charfi C, Zgheib A, Larocque A, Danalache BA, Ouanouki A, Béliveau R, Marsolais C, ANNABI B (2022) The peptide-drug conjugate TH1902: A new sortilin receptor-mediated cancer therapeutic against ovarian and endometrial cancers.  Cancers  14(8):1877